Andreas Argyrides
Stock Analyst at Oppenheimer
(4.27)
# 1,362
Out of 4,399 analysts
391
Total ratings
44.1%
Success rate
9.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SVRA Savara | Maintained: Buy | $11 | $5.09 | +116.11% | 6 | Jun 3, 2026 | |
| DYN Dyne Therapeutics | Reiterated: Buy | $40 | $17.73 | +125.67% | 9 | May 21, 2026 | |
| AQST Aquestive Therapeutics | Reiterated: Buy | $8 | $3.99 | +100.50% | 19 | May 15, 2026 | |
| UTHR United Therapeutics | Rated: Hold | n/a | $544.10 | - | 19 | May 11, 2026 | |
| LRMR Larimar Therapeutics | Rated: Hold | n/a | $3.44 | - | 8 | May 11, 2026 | |
| BNTC Benitec Biopharma | Rated: Hold | n/a | $10.39 | - | 3 | May 11, 2026 | |
| LQDA Liquidia | Rated: Hold | n/a | $65.25 | - | 17 | May 11, 2026 | |
| GOSS Gossamer Bio | Rated: Hold | n/a | $0.156 | - | 19 | May 11, 2026 | |
| MNPR Monopar Therapeutics | Rated: Hold | n/a | $59.73 | - | 4 | May 11, 2026 | |
| KROS Keros Therapeutics | Rated: Hold | n/a | $9.93 | - | 17 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $17.49 | - | 28 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $9.25 | - | 18 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.63 | - | 8 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $5 | $1.62 | +208.64% | 4 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $105 → $98 | $61.27 | +59.95% | 5 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $10 | $3.89 | +157.07% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 | $35.48 | +74.75% | 2 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $20.49 | +104.98% | 1 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.41 | +538.30% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 | $15.11 | +144.87% | 18 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $750 | $2.39 | +31,280.75% | 14 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.783 | - | 13 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0171 | n/a | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $155 | $10.59 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 → $75 | $0.11 | n/a | 18 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $105 | $15.26 | n/a | 13 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.149 | n/a | 13 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $10.97 | n/a | 7 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $21 | $6.13 | n/a | 25 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 | $23.42 | n/a | 8 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $78 → $80 | $56.17 | n/a | 22 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $4 | $11.71 | n/a | 11 | Feb 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $207 → $225 | $209.79 | n/a | 30 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.9315 | n/a | 6 | Aug 25, 2022 |
Savara
Jun 3, 2026
Maintained: Buy
Price Target: $11
Current: $5.09
Upside: +116.11%
Dyne Therapeutics
May 21, 2026
Reiterated: Buy
Price Target: $40
Current: $17.73
Upside: +125.67%
Aquestive Therapeutics
May 15, 2026
Reiterated: Buy
Price Target: $8
Current: $3.99
Upside: +100.50%
United Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $544.10
Upside: -
Larimar Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $3.44
Upside: -
Benitec Biopharma
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $10.39
Upside: -
Liquidia
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $65.25
Upside: -
Gossamer Bio
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $0.156
Upside: -
Monopar Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $59.73
Upside: -
Keros Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $9.93
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $17.49
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $9.25
Upside: -
Apr 27, 2026
Rated: Hold
Price Target: n/a
Current: $3.63
Upside: -
Apr 24, 2026
Maintained: Buy
Price Target: $7 → $5
Current: $1.62
Upside: +208.64%
Apr 24, 2026
Maintained: Buy
Price Target: $105 → $98
Current: $61.27
Upside: +59.95%
Mar 16, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $3.89
Upside: +157.07%
Feb 25, 2026
Reiterated: Buy
Price Target: $62
Current: $35.48
Upside: +74.75%
Jan 23, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $20.49
Upside: +104.98%
Nov 11, 2025
Reiterated: Buy
Price Target: $9
Current: $1.41
Upside: +538.30%
Oct 9, 2025
Maintained: Buy
Price Target: $37
Current: $15.11
Upside: +144.87%
Aug 11, 2025
Reiterated: Buy
Price Target: $750
Current: $2.39
Upside: +31,280.75%
Jul 17, 2025
Rated: Hold
Price Target: n/a
Current: $0.783
Upside: -
Mar 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.0171
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: $155
Current: $10.59
Upside: n/a
Nov 13, 2024
Maintained: Buy
Price Target: $5 → $75
Current: $0.11
Upside: n/a
Aug 13, 2024
Maintained: Hold
Price Target: $105
Current: $15.26
Upside: n/a
Mar 14, 2024
Reiterated: Buy
Price Target: $2
Current: $0.149
Upside: n/a
Mar 6, 2024
Rated: Buy
Price Target: $29
Current: $10.97
Upside: n/a
Mar 5, 2024
Reiterated: Hold
Price Target: $21
Current: $6.13
Upside: n/a
Mar 1, 2024
Reiterated: Buy
Price Target: $57
Current: $23.42
Upside: n/a
Feb 23, 2024
Reiterated: Hold
Price Target: $78 → $80
Current: $56.17
Upside: n/a
Feb 22, 2024
Maintained: Buy
Price Target: $7 → $4
Current: $11.71
Upside: n/a
Feb 8, 2024
Rated: Buy
Price Target: $207 → $225
Current: $209.79
Upside: n/a
Aug 25, 2022
Rated: Hold
Price Target: n/a
Current: $0.9315
Upside: n/a